Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 5 of 5 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/01/18
End: 01/30/20
Due: 01/30/21
Phase: N/A
Priority: Normal
Start: 06/30/20
End: 07/31/20
Due: 07/31/21
Phase: N/A
Priority: Normal
Start: 02/01/18
End: 06/01/18
Due: 06/01/19
Phase: N/A
Priority: Normal
Start: 06/01/19
End: 02/01/20
Due: 02/01/21
Phase: N/A
Priority: Normal
Start: 04/01/18
End: 09/01/18
Due: 09/01/19
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Phaco-UCP Versus Phaco Alone for OAG and Cataract | NCT04430647 | Ameera Gamal Abdelhameed | user2@example.com | None | 2018-03-01 | 2020-01-30 | 2021-01-30 | - | - | 2025-07-14 |
| Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis | NCT04451239 | Ameera Gamal Abdelhameed | user2@example.com | None | 2020-06-30 | 2020-07-31 | 2021-07-31 | - | - | 2025-07-14 |
| Corneal Tomographic Parameters in TGD | NCT04433936 | Ameera Gamal Abdelhameed | user2@example.com | None | 2018-02-01 | 2018-06-01 | 2019-06-01 | - | - | 2025-07-14 |
| Intravitreal Ranibizumab in Recurrent ROP | NCT04539106 | Ameera Gamal Abdelhameed | user2@example.com | None | 2019-06-01 | 2020-02-01 | 2021-02-01 | - | - | 2025-07-14 |
| Long Term Outcome of Intravitreal Ranibizumab for ROP | NCT04537065 | Ameera Gamal Abdelhameed | user2@example.com | None | 2018-04-01 | 2018-09-01 | 2019-09-01 | - | - | 2025-07-14 |